Dedication to biosimilars
We put a lot on the line to advance biotechnology nearly four decades ago, and we’re continuing to do so with biosimilars. With an investment of close to $2 billion across 10 biosimilar medicines, you can be sure that we’re committed long term.
Our four-decade investment in biologics demonstrates an unparalleled experience in researching, developing, and manufacturing medicines, and we’re applying that experience to develop biosimilars across multiple therapeutic areas.
Substantial expertise and infrastructure
Amgen has expertise, global infrastructure, and capital to maintain supply reliability across our entire portfolio of biologics, so you can be sure our medicines will be there for every patient who needs them, every time.1
Delivering quality, reliably supplied biologic and biosimilar medicines is made possible with Amgen’s global infrastructure that is strengthened through the implementation of next-generation manufacturing.1
Amgen has a long-standing commitment to innovation in biotechnology and we are well on our way to establishing new standards of excellence that we expect will shape the future of manufacturing. These new standards involve incorporating new technologies, processes, and equipment that make the production process more efficient, consistent, versatile, and demand-driven.
Reference: 1. Amgen. Unlocking the Potential of Biology for Patients.
Published August 2016. Accessed April 25, 2018.
Next: Impacts of